The Left Ventricular Dysfunction drugs in development market research report provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Left Ventricular Dysfunction. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued products.

GlobalData tracks six drugs in development for Left Ventricular Dysfunction by seven companies/universities/institutes. The top development phase for Left Ventricular Dysfunction is phase i with two drugs in that stage. The Left Ventricular Dysfunction pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Left Ventricular Dysfunction pipeline products market are: Mesoblast, Tasly Pharmaceutical Group and Innopharmax.

The key targets in the Left Ventricular Dysfunction pipeline products market include Beta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2), Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ADRB3), and Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1).

The key mechanisms of action in the Left Ventricular Dysfunction pipeline product include Alpha 1 Adrenergic Receptor (ADRA1) Antagonist with one drug in Phase III. The Left Ventricular Dysfunction pipeline products include three routes of administration with the top ROA being Intracardiac and two key molecule types in the Left Ventricular Dysfunction pipeline products market including Cell Therapy, and Small Molecule.

Left Ventricular Dysfunction overview

Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention, dizziness, fatigue, weakness, irregular heart beat, and congested lungs. Risk factors include high blood pressure, diabetes, sleep apnea, alcoholism, and coronary artery disease.

For a complete picture of Left Ventricular Dysfunction’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.